In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- Posters against HIV stigma defaced in ‘homophobic vandalism’on July 23, 2019 at 7:23 am
Posters designed to end the stigma around HIV have been defaced with white paint in an act of ‘homophobic vandalism’. The posters show two men lying next to one another, along with the message ... […]
- Novel Drug Being Developed for HIV Prevention and Cancer Indications Demonstrates Best-in-Class Potencyon July 23, 2019 at 7:20 am
OTTAWA, Ontario, July 23, 2019 /PRNewswire/ -- Orion Biotechnology Canada Ltd. today announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine ... […]
- Connection to HIV care helps hardly reached US populations suppress the viruson July 22, 2019 at 10:35 pm
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to ... […]
- WHO: 'Strong' Rec for Dolutegravir for HIV, Even in Young Womenon July 22, 2019 at 2:53 pm
MEXICO CITY -- Dolutegravir (Tivicay) is strongly recommended as both first- and second-line therapy for HIV, including for pregnant women and those who may become pregnant, according to updated ... […]
- Even After Decade of Treatment, HIV Can Hide in Spinal Fluidon July 22, 2019 at 2:12 pm
Researchers also suspect the virus may be linked to cognitive issues. Share on Pinterest Researchers are learning more about the long-term effects of HIV. Getty Images Since the height of the HIV and ... […]
- 'Man-Made Disasters' Stymie Progress on Global HIV Epidemicon July 22, 2019 at 12:47 pm
MEXICO CITY -- While certain countries have experienced great success in combating the HIV epidemic, others are continuing to face ongoing challenges, fueled by sporadic outbreaks, lack of response, ... […]
- The future of HIV treatments will change dramatically in the next decade, Citi says. These 3 companies could be the biggest winners.on July 22, 2019 at 12:11 pm
An envelope. It indicates the ability to send an email. A stylized bird with an open mouth, tweeting. The letter F. A stylized letter F. The word "in". An image of a chain link. It symobilizes a ... […]
- Physician Counseling After HIV Diagnosis Could Stem Epidemicon July 22, 2019 at 11:58 am
MEXICO CITY — When Mahesh Swaminathan, MD, has to deliver an HIV diagnosis to a patient, he does not know exactly what will happen, but he usually expects "a serious freak out," if only briefly. "You ... […]
- Signature Health offers free HIV testing at various locations, including Lakewood and Beachwoodon July 22, 2019 at 10:59 am
LAKEWOOD, Ohio -- The CDC (Centers for Disease Control and Prevention) has reported that despite advances in medical treatment, the diagnosis of new HIV infections has remained stable across the ... […]
- Groundbreaking HIV drug safe to use in women of reproductive ageon July 22, 2019 at 9:45 am
A groundbreaking HIV drug is safe to use by women who want to get pregnant after a review found that the risk of birth defects is lower than first thought. The World Health Organization has updated ... […]
via Google News and Bing News